Literature DB >> 21216324

Optimal screening mammography reading volumes; evidence from real life in the East Midlands region of the NHS Breast Screening Programme.

E Cornford1, J Reed, A Murphy, R Bennett, A Evans.   

Abstract

AIM: To assess real-life reader performance as a function of both volume of mammograms read and reading experience in a multicentre cohort.
MATERIALS AND METHODS: Thirty-seven film readers from the East Midlands Breast Screening Programme had 3 years of consecutive screen reading results available for comparison. Markers of screening performance as the first film reader [cancer detection rates, small cancer detection rates, recall rates, positive predictive value of recall (PPV), and missed cancers] were compared with both volume of films read and years of film reading experience. For reading volume, readers were categorized according to film reading volume over the 3 year period: < 15,000 (i.e., on average less than the recommended 5000/year); 15-< 20,000; 20-< 25,000; and ≥ 25,000. For years of experience, readers were categorized into the following groups: < 5 years, 5-< 10 years, 10-< 15 years, and 15-< 20 years.
RESULTS: There was no evidence to suggest a relationship between years of film reading experience and film-reading performance. For reading volume, there was a significant difference in the distribution of cancer-detection rate between the four groups (p=0.01); however, there was no difference in small cancer-detection rates, missed cancers or PPV. The median cancer detection rate in the high-volume group (≥ 25,000 mammograms/3 years) was significantly lower than the other groups combined (6.9 per 1000 women screened versus 7.9 per 1000 women screened). The lowest median recall rate was also in the high-volume group, whilst those readers not meeting the NHSBSP minimum requirement had the highest median recall rate; however, there was borderline evidence to suggest a difference in the distribution of recall rates between the four groups.
CONCLUSION: The data from the East Midlands do not provide any evidence for reducing the threshold volume of 5000 cases /year. However, there appears to be an upper limit above which reader performance deteriorates in terms of lower cancer-detection rates. With the imminent expansion of the programme, this has implications for service quality. These higher-volume readers should be encouraged to recall more borderline cases to assessment. Analysis of national data is recommended to further evaluate these findings.
Copyright © 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21216324     DOI: 10.1016/j.crad.2010.09.014

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  4 in total

1.  How Many of the Biopsy Decisions Taken at Inexperienced Breast Radiology Units Were Correct?

Authors:  Özlem Demircioğlu; Meral Uluer; Erkin Arıbal
Journal:  J Breast Health       Date:  2017-01-01

2.  Factors associated with breast screening radiologists' annual mammogram reading volume in Italy.

Authors:  Doralba Morrone; Livia Giordano; Franca Artuso; Daniela Bernardi; Chiara Fedato; Alfonso Frigerio; Daniela Giorgi; Carlo Naldoni; Gianni Saguatti; Daniela Severi; Mario Taffurelli; Daniela Terribile; Leonardo Ventura; Lauro Bucchi
Journal:  Radiol Med       Date:  2016-03-31       Impact factor: 3.469

3.  Performance of 4 years of population-based mammography screening for breast cancer combined with ultrasound in Tyrol / Austria.

Authors:  Sabine Geiger-Gritsch; Martin Daniaux; Wolfgang Buchberger; Rudolf Knapp; Willi Oberaigner
Journal:  Wien Klin Wochenschr       Date:  2017-12-05       Impact factor: 1.704

4.  Addressing the challenge of assessing physician-level screening performance: mammography as an example.

Authors:  Elizabeth S Burnside; Yunzhi Lin; Alejandro Munoz del Rio; Perry J Pickhardt; Yirong Wu; Roberta M Strigel; Mai A Elezaby; Eve A Kerr; Diana L Miglioretti
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.